

AssayMax™ Human alpha-Fetoprotein ELISA Kit

Assaypro LLC 3400 Harry S Truman Blvd St. Charles, MO 63301 T (636) 447-9175 F (636) 395-7419 www.assaypro.com

For any questions regarding troubleshooting or performing the assay, please contact our support team at support@assaypro.com.

Thank you for choosing Assaypro.

Assay Summary

Step 1. Add 50 μ l of Standard or Sample per well. Incubate 2 hours.

Step 2. Wash, then add 50 μ l of Biotinylated Antibody per well. Incubate 1 hour.

Step 3. Wash, then add 50 μ l of SP Conjugate per well. Incubate 30 minutes.

Step 4. Wash, then add 50 μ l of Chromogen Substrate per well. Incubate 12 minutes.

Step 5. Add 50 μ l of Stop Solution per well. Read at 450 nm immediately.

Symbol Key



Consult instructions for use.

Assay Template

12								
11								
10								
6								
∞								
7								
9								
.c								
4								
ю								
2								
1								
	Ą	В	3	Q	3	Ŧ	9	I

AssayMax™ Human alpha-Fetoprotein (AFP) ELISA Kit

Catalog No. EF6011-1
Sample insert for reference use only

Introduction

Alpha-fetoprotein (AFP, alpha-fetoglobulin) is a fetal-specific glycoprotein with a molecular weight of approximately 70 kDa. It is expressed in the embryonic liver by cells of the vitelline sac and by the fetal intestinal tract in the first trimester of pregnancy (1). After birth, the synthesis of alpha-fetoprotein decreases rapidly. In adults, alpha-fetoprotein level is low but detectable (2). Alpha-fetoprotein has no known function in healthy adults. High levels of alpha-fetoprotein in an adult individual may be associated with a hepatocellular carcinoma (HCC), malignant tumor of the liver (1, 3). Thus, the concentration of alpha-fetoprotein in serum can be measured as a first step in HCC diagnosis (4-5). Moreover the elevated level of alpha-fetoprotein has been observed in lung cancer (6), gastric cancer (7-8), yolk sac tumor, and adenocarcinoma (9).

Principle of the Assay

The AssayMax™ Human alpha-Fetoprotein ELISA (Enzyme-Linked Immunosorbent Assay) Kit is designed for detection of alpha-fetoprotein in human plasma and serum samples. This assay employs a quantitative sandwich enzyme immunoassay technique that measures human alpha-fetoprotein in approximately 4 hours. A polyclonal antibody specific for human alpha-fetoprotein has been pre-coated onto a 96-well microplate with removable strips. Alpha-fetoprotein in standards and samples is sandwiched by the immobilized antibody and a biotinylated polyclonal antibody specific for human alpha-fetoprotein, which is recognized by a streptavidin-peroxidase (SP) conjugate. All unbound material is washed away and a peroxidase enzyme substrate is added. The color development is stopped and the intensity of the color is measured.

Caution and Warning

- This product is for Research Use Only and is not intended for use in diagnostic procedures.
- Prepare all reagents (diluent buffer, wash buffer, standard, biotinylated antibody, and SP conjugate), as instructed, prior to running the assay.

- Prepare all samples prior to running the assay. The dilution factors for the samples are suggested in this insert. However, the user should determine the optimal dilution factor.
- Spin down the SP conjugate vial and the biotinylated antibody vial before opening and using contents.
- The Stop Solution is an acidic solution.
- The kit should not be used beyond the expiration date.

Reagents

- Human alpha-Fetoprotein Microplate: A 96-well polystyrene microplate (12 strips of 8 wells) coated with a polyclonal antibody against human alpha-fetoprotein.
- Sealing Tapes: Each kit contains 3 precut, pressure sensitive sealing tapes that can be cut to fit the format of the individual assay.
- Human alpha-Fetoprotein Standard: Human alpha-fetoprotein in a buffered protein base (52 ng, lyophilized).
- Biotinylated Human alpha-Fetoprotein Antibody (50x): A 50-fold concentrated biotinylated polyclonal antibody against human alphafetoprotein (120 µl).
- MIX Diluent Concentrate (10x): A 10-fold concentrated buffered protein base (30 ml).
- Wash Buffer Concentrate (20x): A 20-fold concentrated buffered surfactant (30 ml, 2 bottles).
- SP Conjugate (100x): A 100-fold concentrate (80 μl).
- Chromogen Substrate (1x): A stabilized peroxidase chromogen substrate tetramethylbenzidine (7 ml).
- Stop Solution (1x): A 0.5 N hydrochloric acid solution to stop the chromogen substrate reaction (11 ml).

Storage Condition

- Upon arrival, immediately store components of the kit at recommended temperatures up to the expiration date.
- Store SP Conjugate and Biotinylated Antibody at -20°C.
- Store Microplate, Diluent Concentrate (10x), Wash Buffer, Stop Solution, and Chromogen Substrate at 2-8°C.
- Unused microplate wells may be returned to the foil pouch with the desiccant packs and resealed. May be stored for up to 30 days in a vacuum desiccator.
- Store Standard at 2-8°C before reconstituting with Diluent and at -20°C after reconstituting with Diluent.

Other Supplies Required

- Microplate reader capable of measuring absorbance at 450 nm
- Pipettes (1-20 μl, 20-200 μl, 200-1000 μl, and multiple channel)
- Deionized or distilled reagent grade water

Sample Collection, Preparation, and Storage

- Plasma: Collect plasma using one-tenth volume of 0.1 M sodium citrate as an anticoagulant. Centrifuge samples at 3000 x g for 10 minutes and collect plasma. A 2-fold sample dilution is suggested into MIX Diluent; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles (EDTA or Heparin can also be used as an anticoagulant).
- **Serum:** Samples should be collected into a serum separator tube. After clot formation, centrifuge samples at 3000 x g for 10 minutes and remove serum. A 2-fold sample dilution is suggested into MIX Diluent; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.

Applicable samples may also include biofluids, cell culture, and tissue homogenates. If necessary, user should determine optimal dilution factor depending on application needs.

Refer to Dilution Guidelines for further instruction.

	Guidelines for Dilutions of 100-fold or Greater				
	(for reference only; please follow the insert for specific dilution suggested)				
	100x		10000x		
A)	4 μl sample : 396 μl buffer (100x) = 100-fold dilution Assuming the needed volume is less than or equal to 400 μl.	A) B)	4 μl sample : 396 μl buffer (100x) 4 μl of A : 396 μl buffer (100x) = 10000-fold dilution Assuming the needed volume is less than or equal to 400 μl.		
	1000x		100000x		
A) B)	4 μl sample : 396 μl buffer (100x) 24 μl of A : 216 μl buffer (10x) = 1000-fold dilution	A) B) C)	4 μl sample : 396 μl buffer (100x) 4 μl of A : 396 μl buffer (100x) 24 μl of B : 216 μl buffer (10x) = 100000-fold dilution		
	Assuming the needed volume is less than or equal to 240 μl.		Assuming the needed volume is less than or equal to 240 μl.		

Reagent Preparation

- Freshly dilute all reagents and bring all reagents to room temperature before use.
- MIX Diluent Concentrate (10x): Dilute the MIX Diluent Concentrate 10fold with reagent grade water to produce a 1x solution. When diluting
 the concentrate, make sure to rinse the bottle thoroughly to extract any
 precipitates left in the bottle. Mix the 1x solution gently until the crystals
 have completely dissolved. Store for up to 30 days at 2-8°C.
- Human alpha-Fetoprotein Standard: Reconstitute the Human alpha-Fetoprotein Standard (52 ng) with 1.3 ml of MIX Diluent to generate a 40 ng/ml standard stock solution. Allow the vial to sit for 10 minutes with gentle agitation prior to making dilutions. Prepare duplicate or triplicate standard points by serially diluting from the standard stock solution (40 ng/ml) 2-fold with equal volume of MIX Diluent to produce 20, 10, 5, 2.5, 1.25, and 0.625 ng/ml solutions. MIX Diluent serves as the zero standard (0 ng/ml). Any remaining stock solution should be stored at -20°C and used within 30 days. Avoid repeated freeze-thaw cycles.

Standard Point	Dilution	[AFP] (ng/ml)
P1	1 part Standard (40 ng/ml)	40
P2	1 part P1 + 1 part MIX Diluent	20
Р3	1 part P2 + 1 part MIX Diluent	10
P4	1 part P3 + 1 part MIX Diluent	5.0
P5	1 part P4 + 1 part MIX Diluent	2.5
P6	1 part P5 + 1 part MIX Diluent	1.25
P7	1 part P6 + 1 part MIX Diluent	0.625
P8	MIX Diluent	0.0

- Biotinylated Human alpha-Fetoprotein Antibody (50x): Spin down the antibody briefly and dilute the desired amount of the antibody 50-fold with MIX Diluent to produce a 1x solution. The undiluted antibody should be stored at -20°C.
- Wash Buffer Concentrate (20x): Dilute the Wash Buffer Concentrate 20fold with reagent grade water to produce a 1x solution. When diluting
 the concentrate, make sure to rinse the bottle thoroughly to extract any
 precipitates left in the bottle. Mix the 1x solution gently until the crystals
 have completely dissolved.
- SP Conjugate (100x): Spin down the SP Conjugate briefly and dilute the
 desired amount of the conjugate 100-fold with MIX Diluent to produce a
 1x solution. The undiluted conjugate should be stored at -20°C.

Assay Procedure

- Prepare all reagents, standard solutions, and samples as instructed. Bring all reagents to room temperature before use. The assay is performed at room temperature (20-25°C).
- Remove excess microplate strips from the plate frame and return them
 immediately to the foil pouch with desiccants inside. Reseal the pouch
 securely to minimize exposure to water vapor and store in a vacuum
 desiccator.
- Add 50 µl of Human alpha-Fetoprotein Standard or sample to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 2 hours. Start the timer after the last addition.
- Wash the microplate manually or automatically using a microplate washer. Invert the plate and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If washing manually, wash five times with 200 μl of Wash Buffer per well. Invert the plate each time and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If using a microplate washer, wash six times with 300 μl of Wash Buffer per well; invert the plate and hit 4-5 times on absorbent material to completely remove the liquid.
- Add 50 µl of Biotinylated Human alpha-Fetoprotein Antibody to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 1 hour.
- Wash the microplate as described above.
- Add 50 µl of SP Conjugate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 30 minutes. Turn on the microplate reader and set up the program in advance.
- Wash the microplate as described above.
- Add 50 µl of Chromogen Substrate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Incubate in ambient light for 12 minutes or until the optimal blue color density develops.
- Add 50 µl of Stop Solution to each well. The color will change from blue to yellow. Gently tap plate to ensure thorough mixing. Break any bubbles that may have formed.
- Read the absorbance on a microplate reader at a wavelength of 450 nm immediately. If wavelength correction is available, subtract readings at 570 nm from those at 450 nm to correct optical imperfections.
 Otherwise, read the plate at 450 nm only. Please note that some unstable black particles may be generated at high concentration points after stopping the reaction for about 10 minutes, which will reduce the readings.

Data Analysis

- Calculate the mean value of the duplicate or triplicate readings for each standard and sample.
- To generate a standard curve, plot the graph using the standard concentrations on the x-axis and the corresponding mean 450 nm absorbance (OD) on the y-axis. The best fit line can be determined by regression analysis using log-log or four-parameter logistic curve fit.
- Determine the unknown sample concentration from the Standard Curve and multiply the value by the dilution factor.

Typical Data


The typical data is provided for reference only. Individual laboratory
means may vary from the values listed. Variations between laboratories
may be caused by technique differences.

Standard Point	ng/ml	OD	Average OD
P1	40	2.042	2.008
, -		1.974	2.000
P2	20	1.329	1.328
' -		1.327	1.020
P3	10	0.806	0.782
- 13		0.758	0.702
P4	5.0	0.478	0.460
1 7	5.0	0.442	0.400
P5	2.5	0.263	0.276
13		0.289	0.270
P6	1.25	0.171	0.177
10	1.25	0.183	0.177
P7	0.625	0.133	0.135
	0.023	0.137	0.155
P8	0.0	0.081	0.082
10	0.0	0.083	0.002
Sample: Poo	oled Normal	0.216	0.201
Sodium Citrat	e Plasma (2x)	0.186	0.201
Sample: Poo	oled Normal	0.302	0.211
Serun	n (2x)	0.320	0.311

Standard Curve

 The curve is provided for illustration only. A standard curve should be generated each time the assay is performed.

Human alpha-Fetoprotein Standard Curve



Reference Value

- Normal human alpha-fetoprotein plasma and serum levels range from 1 – 8 ng/ml.
- Plasma and serum samples from healthy adults were tested (n=20). On average, human alpha-fetoprotein level was 4.9 ng/ml.

Sample	n	Average Value (ng/ml)
Pooled Normal Plasma	10	3.3
Pooled Normal Serum	10	6.4

Performance Characteristics

- The minimum detectable dose of human alpha-fetoprotein as calculated by 2SD from the mean of a zero standard was established to be 0.38 ng/ml.
- Intra-assay precision was determined by testing three plasma samples twenty times in one assay.
- Inter-assay precision was determined by testing three plasma samples in twenty assays.

	Intra-Assay Precision			Inter-Assay Precision		
Sample	1	2	3	1	2	3
n	20	20	20	20	20	20
CV (%)	4.4%	3.7%	4.3%	11.2%	9.7%	10.6%
Average CV (%)		4.1%			10.5%	

Spiking Recovery

 Recovery was determined by spiking one plasma and one serum sample with different alpha-fetoprotein concentrations.

Sample	Unspiked Sample (ng/ml)	Spiking Value (ng/ml)	Expected	Observed	Recovery (%)
		11.203	13.932	15.205	109%
Plasma	2.729	2.752	5.481	5.785	106%
		0.831	3.560	3.245	91%
		11.203	14.870	15.648	105%
Serum	3.667	2.752	6.419	7.062	110%
		0.831	4.498	4.494	100%
Average Recovery (%)					104%

Linearity

• Plasma and serum samples were serially diluted to test for linearity.

Average Percentage of Expected Value (%)					
Sample Dilution	Plasma	Serum			
1x	96%	95%			
2x	101%	98%			
4x	105%	104%			

Cross-Reactivity

Species	Cross-Reactivity (%)
Canine	<30%
Bovine	<30%
Equine	None
Monkey	<40%
Mouse	None
Rat	None
Swine	None
Rabbit	None

Troubleshooting

Issue	Causes	Course of Action
	Use of improper	Check the expiration date listed before use.
	components	 Do not interchange components from different lots.
		 Check that the correct wash buffer is being used.
		 Check that all wells are empty after aspiration.
	Improper wash step	 Check that the microplate washer is dispensing properly.
		If washing by pipette, check for proper pipetting
드	6 1 1: 6	technique.
Low Precision	Splashing of reagents while loading wells	Pipette properly in a controlled and careful manner.
Pre	Inconsistent volumes	Pipette properly in a controlled and careful manner.
3	loaded into wells	Check pipette calibration.
Ď		Check pipette for proper performance.
	Insufficient mixing of	Thoroughly agitate the lyophilized components after
	reagent dilutions	reconstitution.
		Thoroughly mix dilutions.
	Improperly sealed	 Check the microplate pouch for proper sealing. Check that the microplate pouch has no punctures.
	microplate	Check that three desiccants are inside the microplate
	meropiate	pouch prior to sealing.
	Microplate was left	Each step of the procedure should be performed
nal	unattended between	uninterrupted.
igi	steps	
h S	Omission of step	 Consult the provided procedure for complete list of steps.
lig.	Steps performed in	 Consult the provided procedure for the correct order.
×	incorrect order	
lly Low or Intensity	Insufficient amount of	Check pipette calibration.
en e	reagents added to wells	Check pipette for proper performance.
⊒ <u>≺</u>	Wash step was skipped	 Consult the provided procedure for all wash steps.
ed	Improper wash buffer	 Check that the correct wash buffer is being used.
Unexpectedly Low or High Signal Intensity	Improper reagent	Consult reagent preparation section for the correct
ğ	preparation	dilutions of all reagents.
ne,	Insufficient or prolonged incubation	Consult the provided procedure for correct incubation
Ō	prolonged incubation periods	time.
	pe003	Sandwich ELISA: If samples generate OD values higher
ب		than the highest standard point (P1), dilute samples
证		further and repeat the assay.
ve	Non-optimal sample	 Competitive ELISA: If samples generate OD values lower
ă	dilution	than the highest standard point (P1), dilute samples
Þ		further and repeat the assay.
lar		User should determine the optimal dilution factor for
Deficient Standard Curve Fit	Contoni (samples.
Sta	Contamination of	A new tip must be used for each addition of different samples or reagents during the assay procedure.
nt	reagents Contents of wells	samples or reagents during the assay procedure. • Verify that the sealing film is firmly in place before placing
cie	evaporate	the assay in the incubator or at room temperature.
efi	craporate	Pipette properly in a controlled and careful manner.
۵	Improper pipetting	Check pipette calibration.
	proper pipettills	Check pipette cambration: Check pipette for proper performance.
		check pipette for proper performance.

Insufficient mixing of reagent dilutions	 Thoroughly agitate the lyophilized components after reconstitution. Thoroughly mix dilutions.
--	--

References

- (1) Gomaa AI et al. (2009) World J Gastroenterol. 15(11):1301-1314.
- (2) Blohm ME et al. (1998) Pediatr Hematol Oncol. 15(2):135-142.
- (3) Sell S. (2008) Tumour Biol. 29(3):161-180.
- (4) Maringhini A et al. (1988) Digestive Diseases and Sciences. 33(1):47-51.
- (5) Chen L et al. (2010) Ann Surg Oncol. 17(9):2518-2525.
- (6) Hiroshima K et al. (2002) Pathol Int. 52:46-53.
- (7) Chen J et al. (2003) Dig Dis. 21:357-362.
- (8) Kelleher J et al. (1974) Gut. 15:401-403.
- (9) Pauniaho SL et al. (2010) Tumour Biol. 31(4):261-265.

Version 2.8